References
- SuKYChenHYLiKCPretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerJ Clin Oncol201230443344022215752
- MayoCBertran-AlamilloJMolina-VilaMÁGiménez-CapitánACostaCRosellRPharmacogenetics of EGFR in lung cancer: perspectives and clinical applicationsPharmacogenomics201213778980222594511
- MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
- MokTSWuYLThongprasertSGefitinib or carboplatin paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
- MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
- OxnardGRArcilaMEChmieleckiJLadanyiMMillerVAPaoWNew strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancerClin Cancer Res201117175530553721775534
- JiangSXYamashitaKYamamotoMEGFR genetic heterogeneity of non-small-cell lung cancers contributing to acquired gefitinib resistanceInt J Cancer2008123112480248618785203
- RosellRMolinaMACostaCPretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutationsClin Cancer Res20111751160116821233402
- UramotoHYanoSTanakaFT790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKILung Cancer201276112913022335886
- ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
- FujitaYSudaKKimuraHHighly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutationJ Thorac Oncol20127111640164422899358
- DouillardJYShepherdFAHirshVMolecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJ Clin Oncol201028574475220038723
- MaruyamaRNishiwakiYTamuraTPhase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancerJ Clin Oncol200826264244425218779611
- GarassinoMCMartelliOBettiniATAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFRProceedings of the 48th ASCO Annual MeetingJune 1–5, 2012Chicago, USA
- JännePAShawATPereiraJRSelumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 studyLancet Oncol2013141384723200175
- ErcanDXuCYanagitaMReactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsCancer Discov201221093494722961667
- MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
- MackPCHollandWSBurichRAEGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancerJ Thorac Oncol20094121466147219884861
- ShepherdFADanceyJRamlauRProspective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyJ Clin Oncol200018102095210310811675
- FossellaFVDeVoreRKerrRNRandomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study GroupJ Clin Oncol200018122354236210856094
- HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
- BaiHWangZChenKInfluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancerJ Clin Oncol201230253077308322826274